Who makes PG4 vaccine in Buffer 1 with high dose PA-002?

PG4 vaccine in Buffer 1 with high dose PA-002 is developed by Pfizer.

What development phase is PG4 vaccine in Buffer 1 with high dose PA-002 in?

PG4 vaccine in Buffer 1 with high dose PA-002 is in Phase 1.

Last reviewed 2026-04-20 · How we verify

PG4 vaccine in Buffer 1 with high dose PA-002

Pfizer · Phase 1 active Biologic Quality 0/100

At a glance

Generic name	PG4 vaccine in Buffer 1 with high dose PA-002
Sponsor	Pfizer
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PG4 vaccine in Buffer 1 with high dose PA-002 CI brief — competitive landscape report
PG4 vaccine in Buffer 1 with high dose PA-002 updates RSS · CI watch RSS
Pfizer portfolio CI